DOX-MTX-NPs augment p53 mRNA expression in OSCC model in rat: Effects of IV and oral routes

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 19, 2014, Pages 8377-8382

  Abbasi, Mehran Mesgari ^a,b   Khiavi, Monir Moradzadeh ^c   Monfaredan, Amir ^d   Hamishehkar, Hamed ^a   Seidi, Khaled ^a   Jahanban Esfahlan, Rana ^a,b  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Tabriz Unlversity of Medical Sciences   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

DOX MTX NPs; Oral and IV route; Oral squamous cell carcinoma; p53; Rat model

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; MESSENGER RNA; METHOTREXATE; NANOPARTICLE; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG ADMINISTRATION ROUTE; GENETICS; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; MOUTH NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TUMOR CELL CULTURE;

ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DOXORUBICIN; DRUG ADMINISTRATION ROUTES; HUMANS; MALE; METHOTREXATE; MOUTH NEOPLASMS; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908376977     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.19.8377     Document Type: Article

References (35)

1. Abusail M, Dirweesh AM, Salih RA, et al (2013). Expression of EGFR and p53 in Head and Neck Tumors among Sudanese Patients. Asian Pac J Cancer Prev, 14, 6415-8.
2. Bae Y (2010). Drug delivery systems using polymer nanoassemblies for cancer treatment. Ther Deliv, 1, 361-3.
3. Baykara M, Buyukberber S, Ozturk B, et al (2013). Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers. Asian Pac J Cancer Prev, 14, 2557-61.
4. Benival D, PV D (2012). Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm, 423, 554-61.
5. Chen Y, Wan Y, Wang Y, et al (2011). Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine, 6, 2321-6.
6. Cipriani P, Ruscitti P, Carubbi F, et al (2014). Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. Current and Emerging Paradigms. Clin Ther, 36, 427-35.
7. Deng Y, Zhang H (2013). The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics. Int J Nanomedicine, 8, 1835-41.
8. Duong HH, Yung LY (2013). Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment. Int J Pharm, 454, 486-95.
9. Guhagarkar SA, Gaikwad RV, Samad A, et al (2010). Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting. Int J Pharm, 401, 113-22.
10. Hu CM, Aryal S, Zhang L (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv, 1, 323-34.
11. Huang WY, Yang PM, Chang YF, et al (2011). Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol, 81, 510-7.
12. Jahanban Esfahlan R, Zarghami N, Jahanban Esfahlan A, et al (2011a). The possible impact of obesity on androgen, progesterone and estrogen receptors (ERa and ERb) gene expression in breast cancer patients. Breast Cancer, 5, 227-37.
13. Jahanban Esfahlan R, Zarghami N, Rahmati-Yamchi M, et al (2011b). Quantification of Steroid Receptors Gene Expression in Breast Cancer Patients: Possible Correlation with Serum Level of Adipocytokines. Journal of Cancer Therapy, 2, 659-65.
14. Jahanban Esfahlan R, Zarghami N, Valiyari S, et al (2012). Adiponectin Can Affect ER Signaling in Obese Breast Cancer Patients. Journal of Cancer Therapy, 3, 115-21.
15. Jain S, Patil SR, Swarnakar NK, et al (2012). Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (layersomes). Mol Pharm, 9, 2626-35.
16. Jones KR, Lodge-Rigal RD, Reddick RL, et al (1992). Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg, 118, 483-5.
17. Kademani D, Bell RB, Bagheri S, et al (2005). Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg, 63, 1599-605.
18. Kalaria DR, Sharma G, Beniwal V, et al (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res, 26, 492-501.
19. Kim HR, Christensen R, Park NH, et al (2001). Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res, 7, 3079-86.
20. Lasrado S, Moras K, GJ P, et al (2014). Role of concomitant chemoradiation in locally advanced head and neck cancers. Asian Pac J Cancer Prev, 15, 4147-52.
21. Liboiron B, Mayer L (2014). Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther Deliv, 5, 149-71.
22. Lippman SM, Hong WK (2001). Molecular markers of the risk of oral cancer. N Engl J Med, 344, 1323-6.
23. Liu L, Zhang D, Jiao JH, et al (2014). Association between the TP53BP1 rs2602141 A/C polymorphism and cancer risk: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 15, 2917-22.
24. Massano J, Regateiro FS, Januario G, et al (2006). Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg.Oral Med.Oral Pathol.Oral Radiol Endod, 102, 67-76.
25. Mehdipour M, Taghavi ZA, Mesgari AM, et al (2013). Evaluation of the Effect of Two Systemic Doses of HESA-A on Prevention of Induced Tongue Neoplasm in Rats. J Dent Res Dent Clin Dent Prospects, 7, 218-24.
26. Mesgari Abbasi M, Monfaredan A, Hamishehkar H, et al (2014). Novel DOX-MTX NPs improve the OSCC clinical outcome by down regulation of lymph dissemination factor VEGF-C expression in vivo: effect of oral and IV modalities. Asian Pac J Cancer Prev, 15 (15), 6227-32.
27. Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-8.
28. Montoro JR, Ricz HA, Souza L, et al (2008). Prognostic factors in squamous cell carcinoma of the oral cavity. Braz J Otorhinolaryngol, 74, 861-6.
29. Nasiri M, Zarghami N, Nejati Koshki K, et al (2013). Curcumin and Silibinin Inhibit Telomerase Expression in T47D Human Breast Cancer Cells. Asian Pac J Cancer Prev, 14, 3449-53.
30. Rossi B, Schinzari G, Maccauro G, et al (2010). Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord, 11, 34.
31. Salehi R, Hamishehkar H, Eskandani M, et al (2014). Development of dual responsive nanocomposite for simultaneous delivery of anticancer drugs. J.Drug Target.
32. Schliephake H (2003). Prognostic relevance of molecular markers of oral cancer-a review. Int J Oral Maxillofac Surg, 32, 233-45.
33. Tacar O, Sriamornsak P, Dass CR (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol, 65, 157-70.
34. Valiyari S, Jahanban-Esfahlan R, Zare Shahneh F, et al (2013). Cytotoxic and apoptotic activity of Scrophularia oxysepala in MCF-7 human breast cancer cells. Toxicological & Environmental Chemistry, 95, 1208-20.
35. Wang Y, Wei X, Zhang C, et al (2010). Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Ther Deliv, 1, 273-87.